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Abstract
Increased APOBEC3BmRNA levels are associated with a hypermutator phenotype and
poor prognosis in ER-positive breast cancer patients. In addition, a 29.5 kb deletion poly-
morphism of APOBEC3B, resulting in an APOBEC3A-B hybrid transcript, has been associ-
ated with an increased breast cancer risk and the hypermutator phenotype. Here we
evaluated whether the APOBEC3B deletion polymorphism also associates with clinical out-
come of breast cancer. Copy number analysis was performed by quantitative PCR (qPCR)
in primary tumors of 1,756 Dutch breast cancer patients. The APOBEC3B deletion was
found in 187 patients of whom 16 carried a two-copy deletion and 171 carried a one-copy
deletion. The prognostic value of the APOBEC3B deletion for the natural course of the dis-
ease was evaluated among 1,076 lymph-node negative (LNN) patients who did not receive
adjuvant systemic treatment. No association was found between APOBEC3B copy number
values and the length of metastasis-free survival (MFS; hazard ratio (HR) = 1.00, 95% confi-
dence interval (CI) = 0.90–1.11, P = 0.96). Subgroup analysis by ER status also did not
reveal an association between APOBEC3B copy number values and the length of MFS.
The predictive value of the APOBEC3B deletion was assessed among 329 ER-positive
breast cancer patients who received tamoxifen as the first-line therapy for recurrent disease
and 226 breast cancer patients who received first-line chemotherapy for recurrent disease.
No association between APOBEC3B copy number values and the overall response rate
(ORR) to either tamoxifen (odds ratio (OR) = 0.88, 95% CI = 0.69–1.13, P = 0.31) or chemo-
therapy (OR = 0.97, 95% CI = 0.71–1.33, P = 0.87) was found. Thus, in contrast to APO-
BEC3BmRNA levels, the APOBEC3B deletion polymorphism has neither a prognostic nor
a predictive value for breast cancer patients. Although a correlation exists between APO-
BEC3B copy number and mRNA expression, it is relatively weak. This suggests that other
mechanisms exist that may affect and therefore determine the prognostic value of APO-
BEC3BmRNA levels.
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Introduction
Breast cancer, like most cancer types, is a heterogeneous disease. The heterogeneous nature of
breast cancer, however, provides challenges for identifying appropriate markers for disease sus-
ceptibility and progression, as well as treatment selection. Accordingly, transcriptional profil-
ing has identified five molecular subtypes of breast cancer, which differ in prognosis, efficacy of
treatment and preferred site of metastasis [1–5]. More recently, the catalogues of mutations
across human cancers have provided us insight into the mutational processes that drive tumor-
igenesis [6,7]. For breast cancer, five distinct mutational signatures have been defined that con-
tribute in varying degree to the final mutational catalogue of a breast tumor [7]. One of the
most pronounced mutational processes impacting breast tumorigenesis is driven by the AID/
APOBEC family of cytidine deaminases and gives rise to C>T and C>G substitutions at
TpCpN nucleotides. Moreover, this mutational process associates with regional somatic hyper-
mutation or kataegis [6–8].
The APOBEC3 gene cluster is located on chromosome 22q13.1-q13.2 and harbors seven
APOBEC3 genes that have evolved in primates (i.e. APOBEC3A, APOBEC3B, APOBEC3C,
APOBEC3D, APOBEC3F, APOBEC3G and APOBEC3H) [9]. APOBEC3s play a role in intracel-
lular defense through restriction of retroviral infections, but also of infections from the cancer-
associated hepatitis B virus, the human papilloma virus and human T-lymphotropic virus [10].
Moreover, APOBEC3A, APOBEC3B, APOBEC3C and APOBEC3F are also able to inhibit
LINE1 retrotransposition [11,12]. Besides its role in innate immunity, APOBEC3B has recently
been identified as an endogenous source of mutation in breast cancer [13]. APOBEC3BmRNA
expression was found to be upregulated in most breast cancers and tumors expressing high lev-
els of APOBEC3B had a 2-fold increase in mutations compared with tumors expressing low
APOBEC3B levels. This suggests that APOBEC3B, at least in part, underlies the APOBEC-
driven mutational process in breast cancer, but also in other cancers [13,14]. In line with these
findings, high levels of APOBEC3BmRNA were associated with a shorter disease-free survival
in ER-positive, LNN, systemically untreated patients, as well as with earlier recurrence in lumi-
nal subtype patients and with a more aggressive phenotype in Japanese breast cancers [15–17].
Moreover, APOBEC3B expression has been reported to be associated with a strong enrichment
of mitotic and cell cycle-related genes [16].
A 29.5 kb germline deletion between the fifth exon of APOBEC3A and the eighth exon of
APOBEC3B has been identified that essentially removes the complete APOBEC3B coding
region from the genome and generates a fusion transcript of APOBEC3A with the 3’untrans-
lated region (UTR) of APOBEC3B [18]. With a worldwide frequency of 22.5%, the frequency
of the germline APOBEC3B deletion variant varies widely among the different ethnic groups,
ranging from being rare in African and European populations (i.e. 0.9% and 6%, respectively)
to being common in Asian and American populations (i.e. 36.9% and 57.7%, respectively) [18].
Through a genome-wide association study of copy number variation, Long et al. found that the
APOBEC3B deletion variant was associated with an increased risk to develop breast cancer in
Chinese women [19]. This finding was replicated among European [20] and Southeast Iranian
women [21], but not among Swedish women [22]. Interestingly, carriers of the APOBEC3B
deletion were shown to have a greater APOBEC3AmRNA stability resulting in higher APO-
BEC3A levels, increased activity of APOBEC-driven mutational processes and more severe
DNA damage [23,24]. However, the APOBEC3B deletion polymorphism was not associated
with the survival of breast cancer patients [16,22]. Thus, despite that APOBEC3B overexpres-
sion and the APOBEC3B deletion variant both result in a hypermutation phenotype, there
seems to be a difference between the two mechanisms and their association with clinical
outcome.
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To investigate the relation between the APOBEC3B deletion polymorphism and clinical
outcome of 1,756 Dutch breast cancer patients, we explored four different clinical cohorts:
LNN patients who did not receive any adjuvant treatment, lymph node positive (LNP)
patients who did receive adjuvant systemic treatment, hormone-naive ER-positive patients
who received tamoxifen as first-line therapy for recurrent disease and patients that received
first-line chemotherapy for recurrent disease. Furthermore, to investigate the relation between
the clinical outcomes based on the APOBEC3B deletion polymorphism versus APOBEC3B




The retrospective study cohort consisted of 1,756 breast cancer patients who underwent sur-
gery for an invasive primary breast cancer between 1978 and 2001. Inclusion criteria were no
neoadjuvant treatment, no experience of a previous other cancer (except for basal cell carci-
noma or stage Ia/Ib cervical cancer), a minimum of 100 mg of freshly frozen primary tumor tis-
sue available for downstream DNA isolation and DNA available from tissue with a tumor cell
nuclei percentage 30%. Cytosolic ER and PR levels were determined by ligand binding assay
or enzyme immunoassay [25,26]. ER and/or PR positivity was defined by10 fmol/mg cyto-
solic protein and ERBB2 overexpression was defined by a reverse transcriptase qPCR expres-
sion level18 [27]. In total, 796 patients underwent breast-conserving lumpectomy and 960
patients underwent modified radical mastectomy. In addition, 215 patients received adjuvant
hormonal therapy, 308 patients received adjuvant chemotherapy and 6 patients received both
adjuvant hormonal therapy and chemotherapy. There were 1,713 M0 patients and 43 M1
patients. The median age at the time of the primary surgery was 54 years, while the median age
at the start of first-line treatment was 55 years. The clinicopathological variables of the patients
are shown in Table 1.
The total study cohort consists of four specific studies that were grouped together: 1) 1,076
LNN patients who did not receive any adjuvant systemic treatment, 2) 528 LNP patients who
received adjuvant systemic treatment, 3) 329 hormone-naive ER-positive patients who received
first-line tamoxifen therapy for recurrent disease and 4) 226 patients who received first-line che-
motherapy for recurrent disease as detailed in Fig 1. We included all eligible patients fulfilling
the study criteria and the general inclusion criteria specified above. As a consequence 403
patients were included in two studies (i.e. one study in the adjuvant setting and one study in the
advanced setting). The total study population, however, cannot be considered a pure consecu-
tive series, since systemically treated LNN patients were not included. The reason for this is that
we especially wished to study the association of APOBEC3B copy number with the natural
course of the disease in LNN patients, not potentially confounded by adjuvant systemic therapy.
Routine postsurgical follow-up and the definition of time to metastasis for LNN and LNP
patients were as described previously [28]. The median follow-up for the 1,604 LNN and LNP
patients included in the prognostic studies for the analysis of metastasis-free survival (MFS)
was 114 months (range 10–354 months). Of these 1,604 patients, 686 (42.8%) had developed a
distant metastasis and 691 (43.1%) of the 1,604 patients died during follow up. More specifi-
cally, 602 (37.5%) patients died after disease recurrence, whereas 89 (5.5%) patients died with-
out evidence of disease recurrence at last follow-up. These 89 patients were censored at the
date of last follow-up in the analysis of MFS.
Criteria for follow up and response to tamoxifen therapy were defined by standard Interna-
tional Union Against Cancer (Geneva, Switzerland) criteria of tumor response [29]. Complete
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and partial remission (together objective response) was observed in 11 and 48 patients, respec-
tively, whereas 79 patients had progressive disease. From the patients with stable disease, 171
had no change for> 6 months, whereas 20 patients had no change for 6 months. According
to the advice of the European Organization for Research and Treatment of Cancer [30], we
Table 1. Association of APOBEC3B copy number status with clinicopathological variables in 1,756 primary breast cancers.
Variables Deleted Balanced Ampliﬁed P-value
Total number 187 1260 309
Age (in years) 0.54
 40 23 (12.3%) 160 (12.7%) 48 (15.5%)
41–55 82 (43.9%) 498 (39.5%) 116 (37.5%)
56–70 62 (33.2%) 412 (32.7%) 99 (32.0%)
>70 20 (10.7%) 190 (15.1%) 46 (14.9%)
Menopausal status 0.31
Premenopausal 89 (47.6%) 554 (44.0%) 149 (48.2%)
Postmenopausal 98 (52.4%) 706 (56.0%) 160 (51.8%)
Tumor size 1.00
pT1 71 (38.0%) 469 (37.2%) 115 (37.2%)
pT2 + Unknown 96 (51.3%) 661 (52.5%) 163 (52.8%)
pT3 + pT4 20 (10.7%) 130 (10.3%) 31 (10.0%)
Nodal status 0.041
N0 117 (63.6%) 793 (63.5%) 173 (56.5%)
N1-3 23 (12.5%) 212 (17.0%) 67 (21.9%)
N>3 44 (23.9%) 244 (19.5%) 66 (21.6%)
Tumor grade 0.052
Good/Moderate 34 (23.8%) 193 (21.9%) 66 (29.6%)
Poor 109 (76.2%) 689 (78.1%) 157 (70.4%)
Tumor histology 0.29
IDC 129 (83.2%) 833 (80.6%) 196 (78.4%)
ILC 10 (6.5%) 119 (11.5%) 30 (12.0%)
Other 16 (10.3%) 82 (7.9%) 24 (9.6%)
ER status 0.24
Positive 130 (70.3%) 951 (75.8%) 226 (73.9%)
Negative 55 (29.7%) 303 (24.2%) 80 (26.1%)
PR status 0.99
Positive 114 (65.5%) 779 (65.8%) 187 (65.6%)
Negative 60 (34.5%) 404 (34.2%) 98 (34.4%)
HER2 status 0.59
Positive 18 (12.6%) 150 (15.7%) 39 (16.2%)
Negative 125 (87.4%) 807 (84.3%) 201 (83.8%)
Adjuvant systemic therapy 0.17
None 133 (73.5%) 856 (69.9%) 191 (63.0%)
Chemotherapy 26 (14.4%) 219 (17.9%) 63 (20.8%)
Hormonal therapy 22 (12.2%) 146 (11.9%) 47 (15.5%)
Both 0 (0%) 4 (0.3%) 2 (0.7%)
Note: For nodal status, tumor grade, tumor histology, ER, PR and HER2 status and adjuvant systemic therapy the number of patients do not add up to 1,756
because there were missing values for these variables. In addition, for the adjuvant systemic treatment variable: some patients were not eligible for adjuvant
treatment because they were had distant metastasis at the time of primary tumor diagnosis.
doi:10.1371/journal.pone.0161731.t001
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defined overall response as complete and partial remission including stable disease> 6
months. As a result, 230 patients were classified as responders to tamoxifen and 99 patients
showed no response to tamoxifen. The median follow up of patients after start of tamoxifen
therapy was 49 months (range: 4–176 months). At the end of the follow up, 304 (92.4%)
patients had developed tumor progression and were counted as events in the analysis of pro-
gression-free survival (PFS) and 264 patients had died.
Criteria for follow up and response to chemotherapy were similar to those for tamoxifen
therapy with the exception that not all patients were chemotherapy-naïve. In fact, 45 out of 226
patients had received adjuvant chemotherapy. Of those, 33 patients received cyclophospha-
mide/methotrexate/5-fluorouracil (CMF), 11 patients received anthracycline-based chemo-
therapy and 1 patient received both. Complete and partial remission was observed in 12 and 69
patients, respectively, whereas 66 patients had progressive disease. From the 77 patients with
stable disease, 54 had no change for> 6 courses, whereas 23 patients had no change for 6
courses. We defined overall response as complete and partial remission including stable disease
>6 courses. As a result, 135 patients were classified as responders to chemotherapy and 89
patients showed no response to chemotherapy. For two patients the type of response was
ambiguous. The median follow up of patients after start of chemotherapy was 30 months
(range: 4–153 months). Fifty-two patients received consolidation therapy after chemotherapy
and PFS was right censored at two months after the start of consolidation therapy. At this time
Fig 1. Schematic overview of study cohort. In total, this retrospective study consists of 1,756 primary
breast cancers from patients who underwent surgery between 1978 and 2001. Inclusion criteria are specified
in the Materials and Methods section. In the adjuvant setting, there were 1,076 lymph node negative (LNN)
patients who did not receive adjuvant systemic treatment and 528 lymph node positive (LNP) patients who
received adjuvant systemic treatment for the analysis of MFS. In the advanced setting, a group of 329
hormone-naive patients with ER-positive breast cancer received first-line tamoxifen for recurrent disease. Of
these, 145 patients came from the LNN patients group and 73 came from the LNP patients group. The
remaining 111 patients in this group did not qualify for MFS analysis (i.e. 82 patients did not fulfill LNN or LNP
study eligibility criteria and 29 patients already presented with metastasis at the time of diagnosis).
Furthermore, a group of 226 patients received first-line chemotherapy for recurrent disease. Of these, 85
patients came from the LNN patients group and 100 came from the LNP patients group. The remaining 41
patients in this group did not qualify for MFS analysis (i.e. 27 patients did not fulfill LNN or LNP study eligibility
criteria and 14 patients already presented with metastasis at the time of diagnosis).
doi:10.1371/journal.pone.0161731.g001
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point, 138 patients had developed tumor progression and were counted as events in the analy-
sis of PFS. At the end of follow up, 210 patients had died.
This study was approved by the Medical Ethical Committee of the Erasmus Medical Center
Rotterdam, the Netherlands (MEC 02.953). As this is a retrospective study using remaining
material from surgical resection of the patient’s primary tumor, obtaining informed consent
from the patient was not required provided patient records were anonymized and de-identified
prior to analysis. Herewith, we adhered to the Code of Conduct of the Federation of Medical
Scientific Societies in the Netherlands (http://www.fmwv.nl). Results are reported in accor-
dance with the REMARK criteria on clinical reporting [31].
Copy number analysis
Copy number analysis forAPOBEC3B was performed on genomic DNA isolated from fresh-fro-
zen primary tumor sections by qPCR on a Mx3000/3005P machine (Agilent Technologies,
Santa Clara, CA). Briefly, genomic DNA was isolated from two to ten 30 μm cryostat sections
(5–20 mg) with the NucleoSpin Tissue kit (Macherey–Nagel, Düren, Germany) according the
protocol provided by the manufacturer. DNA quantity and quality was assessed by Nanodrop
and the Quant-iT PicoGreen dsDNAHS Assay Kit (Thermo Scientific, Waltham, MA). Next,
0.5X Taqman Copy Number Assay for the APOBEC3B gene (Hs04504055_cn; Thermo Scien-
tific), 0.5X Taqman Copy Number Reference Assay (i.e. for the RNase P gene; Thermo Scien-
tific) and 0.5X ABsolute qPCRMix, low ROX (Thermo Scientific) were added to 20 ng of
genomic DNA in a final volume of 17 μl. Cycling conditions were: 1 cycle of 15 minutes at 95°C
and 45 cycles of 15 seconds at 92°C and 1 minute at 60°C. The MxPro qPCR software v4.10
(Agilent) was used to calculate the cycle threshold (Ct) values. Relative quantification analysis
was performed within the CopyCaller v2.0 software (Thermo Scientific). For this, the ΔCt value
was calculated for each sample by subtracting the Ct value for the target gene (i.e. APOBEC3B)
from the Ct value of the reference gene (i.e. RNase P). In the case of no Ct value for APOBEC3B
after 45 cycles, while the RNase P gene was successfully amplified within 32 cycles for that sam-
ple, the ΔCt value could not be quantified and the sample was designated to have a two-copy
deletion of the APOBEC3B gene. For samples where the ΔCt was quantified, ΔCt values were
converted to calculated copy number values by the CopyCaller software as detailed in S1 Fig.
Then, samples with calculated copy numbers 0.2 were called as two-copy deletion of theAPO-
BEC3B gene, samples with calculated copy numbers>0.20 and 1.41 as one-copy deletion of
the APOBEC3B gene, samples with calculated copy numbers> 1.41 and 3.44 as no copy
number change or balanced and samples with calculated copy numbers> 3.44 as amplified for
the APOBEC3B gene. Furthermore, 325 samples were measured in duplicate distributed over
the 96-well sample plates and each 96-well plate included genomic DNA from breast cancer cell
line OCUB-F as a control since this cell line has a two-copy deletion of APOBEC3B.
Expression analysis
APOBEC3BmRNA expression analysis has been performed previously for 1,491 breast cancer
patients [15]. Extraction of RNA, synthesis of cDNA, reverse transcriptase quantitative PCR
and quantification of transcripts was also described before [32]. Out of the 1,756 patients for
whom we performed APOBEC3B copy number analysis in the current study, APOBEC3B
mRNA expression data was available for 1,132 patients.
Statistical analyses
Because the number of patients carrying a two-copy deletion of APOBEC3B was small (N = 16,
0.91%), we grouped patients with one-copy and two-copy deletions together. A χ2 or Fisher’s
The APOBEC3BDeletion Polymorphism and Clinical Outcome of Breast Cancer
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exact test (when the expected frequency was 5 in any of the groups) was used to evaluate the
association between the APOBEC3B copy number status (i.e. deleted, balanced or amplified)
and the clinicopathological variables. To assess the association between the APOBEC3B copy
number status and the ORR to either first-line tamoxifen treatment or first-line chemotherapy,
we used a logistic regression model to calculate ORs and their 95% CIs. For visualization pur-
poses, we performed survival analysis by the Kaplan-Meier method. The difference between
survival curves for patients with either a deletion, no copy number change, or an amplification
was calculated using the 3-sample logrank test. In addition, univariate Cox proportional haz-
ards regression models including continuous calculated copy number values as covariate were
performed to assess the association between APOBEC3B copy number and survival times (i.e.
MFS in the adjuvant setting and PFS in the advanced setting). Finally, the correlation between
APOBEC3B copy number and APOBEC3B expression was evaluated using Spearman’s rank
correlation. All P-values were two-sided and P-values< 0.05 were considered to be statistically
significant. Analyses were performed using R, version 3.2.3, except for the power and sample
size calculations shown in the Discussion. For these, we used the stpower cox tool in Stata ver-
sion 13.1 (StataCorp, College Station, TX) assuming an alpha of 0.05, a beta of 0.2 (i.e. only in
sample size calculations) and similar covariate standard deviations, allele frequencies, event
probabilities and sample sizes (i.e. only in power calculations) as observed in the current study.
Results
We have performed APOBEC3B copy number analyses among 1,756 primary breast cancers
and found no copy number change among 1,260 breast cancers. A two-copy deletion was iden-
tified in 16 (0.91%) breast cancers, whereas 171 (9.74%) breast cancers had a one-copy deletion.
In addition, we detected an amplified APOBEC3B gene locus in 309 (17.26%) breast cancers.
The minor allele frequency of the APOBEC3B deletion was 5.8% (203/3512) which is similar to
the expected frequency in European population (i.e 6.5%) [18].
Next, we evaluated the association between the APOBEC3B copy number status and the
clinicopathological variables of the 1,756 breast cancer patients. We found that APOBEC3B
copy number status was significantly associated with nodal status (P = 0.041), but not with age,
menopausal status, tumor size, tumor grade, tumor histology, ER, PR andHER2 status, and
adjuvant systemic therapy (Table 1). Despite the significant association between APOBEC3B
copy number status and nodal status, however, no meaningful trend was observed (Table 1).
To assess whether APOBEC3B copy numbers associate with clinical outcome in the adju-
vant setting, we performed Kaplan-Meier survival analysis and Cox regression analysis in 1,604
LNN and LNP patients. No association between APOBEC3B copy number status and the
length of MFS was found (P = 0.14; Fig 2A). Moreover, calculated copy number values were
also not associated with the length of MFS (HR = 0.95, 95% CI = 0.88–1.02, P = 0.17; Table 2).
Because all LNP patients were treated with adjuvant systemic therapy and we specifically
wanted to evaluate the prognostic value of APOBEC3B copy number, we repeated these analy-
ses in the cohort of 1,076 LNN patients that had not received any adjuvant systemic treatment.
Again, we found no association between APOBEC3B copy number status and the length of
MFS (P = 0.84; Fig 2B), nor did we find an association between APOBEC3B calculated copy
number values and the length of MFS (HR = 1.00, 95% CI = 0.90–1.11, P = 0.96; Table 2). Also
when we performed subgroup analysis in 769 ER-positive or 300 ER-negative untreated LNN
patients (i.e. ER status was not available for 7 patients), APOBEC3B copy numbers did not
appear to have any prognostic value (Fig 2C and 2D, Table 2).
To evaluate the predictive value of APOBEC3B copy numbers, we had two cohorts of breast
cancer patients available that were treated with first-line therapy for recurrent disease. First, we
The APOBEC3BDeletion Polymorphism and Clinical Outcome of Breast Cancer
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Fig 2. Kaplan-Meier survival analysis as a function of APOBEC3B copy number status. (A) In 1,604
patients of the lymph node negative (LNN) and lymph node positive (LNP) cohort combined. (B) In 1,076 LNN
patients who did not receive any adjuvant systemic treatment. (C) In 769 ER-positive LNN patients who did not
receive any adjuvant systemic treatment. (D) In 300 ER-negative LNN patients who did not receive any adjuvant
systemic treatment. (E) In 329 ER-positive breast cancer patients who received first-line tamoxifen for recurrent
disease. (F) In 226 breast cancer patients who received first-line chemotherapy for recurrent disease. (G) In 76
breast cancer patients who received first-line CMF-based chemotherapy for recurrent disease. (H) In 150 breast
cancer patients who received first-line anthracycline based chemotherapy for recurrent disease. Differences
between the survival curves were calculated with the 3-sample logrank test.
doi:10.1371/journal.pone.0161731.g002
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evaluated whether the calculated APOBEC3B copy number values could predict the clinical
outcome of first-line tamoxifen therapy in a cohort of 329 hormone-naive breast cancer
patients with ER-positive primary breast cancer. No significant association was observed
between APOBEC3B copy number and the ORR for tamoxifen therapy (OR = 0.88, 95%
CI = 0.69–1.13, P = 0.31; Table 3). Moreover, APOBEC3B copy number status was not associ-
ated with the length of PFS (P = 0.25; Fig 2E), nor were calculated APOBEC3B copy number
values associated with the length of PFS (HR = 1.00, 95% CI = 0.88–1.14, P = 0.96; Table 4) in
this cohort. Thus, APOBEC3B copy number is not a suitable biomarker to predict the type of
response to tamoxifen therapy.
Next, we evaluated whether calculated APOBEC3B copy number values could predict the
outcome of first-line chemotherapy in a cohort of 226 breast cancer patients. The calculated
APOBEC3B copy number values were, however, not found to be associated with the ORR for
chemotherapy (OR = 0.96, 95% CI = 0.71–1.31, P = 0.80; Table 3). In addition, neither APO-
BEC3B copy number status, nor calculated APOBEC3B copy number values were associated
with the length of PFS in these patients (P = 0.42; Fig 2F and HR = 1.06, 95% CI = 0.88–1.29,
P = 0.53; Table 4, respectively). The lack of a significant association with the ORR to chemo-
therapy and the length of PFS was also observed when performing subgroup analysis by type of
chemotherapy (i.e. CMF versus anthracyclines; Table 3, Fig 2G and 2H, Table 4). APOBEC3B
copy number is thus also not a predictive biomarker for the type of response to chemotherapy.
In a previous study, we had analyzed APOBEC3BmRNA expression in 1,491 breast cancer
patients and found that high APOBEC3B expression had prognostic value and was associated
Table 2. Univariate Cox regression analysis to evaluate the association of calculated APOBEC3B copy number values with the length of MFS.
Study cohort N Patients N Events Univariate analysis
HR (95% CI) P-value
LNN+LNP
All patients 1,604 686 0.95 (0.88–1.02) 0.17
LNN
All patients 1,076 366 1.00 (0.90–1.11) 0.96
ER+ patients 769 263 0.93 (0.82–1.06) 0.29
ER- patients 300 101 1.13 (0.94–1.35) 0.20
N, number of; HR, hazard ratio; CI, conﬁdence interval; LNN, lymph node negative; LNP, lymph node positive.
Note: ER status was not available for 7 out of 1,076 patients.
doi:10.1371/journal.pone.0161731.t002
Table 3. Univariate logistic regression analysis of the overall response rate in patients treated with
first-line tamoxifen and in patients treated with first-line chemotherapy for recurrent disease.
Study cohort N Patients Univariate analysis
OR (95% CI) P-value
First-line tamoxifen
All patients 329 0.88 (0.69–1.13) 0.31
First-line chemotherapy
All patients 224 0.96 (0.71–1.31) 0.80
CMF-treated patients 75 1.25 (0.70–2.21) 0.45
Anthracyclin-treated patients 149 0.79 (0.53–1.16) 0.22
N, number of; OR, odds ratio; CI, conﬁdence interval; CMF, cyclophosphamide/methotrexate/5-ﬂuorouracil.
Note: the type of response was ambiguous for 2 patients
doi:10.1371/journal.pone.0161731.t003
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with poor outcome in untreated LNN patients with ER-positive breast cancer [15]. However,
we did not find any association between APOBEC3B copy numbers and clinical outcome in the
current study. As both APOBEC3B expression and APOBEC3B copy number have been associ-
ated with a hypermutator phenotype [13,14,24], we attempted to clarify this discrepancy by
evaluating the correlation between APOBEC3B copy number and APOBEC3BmRNA expres-
sion. Out of the 1,756 patients for whom we performed APOBEC3B copy number analysis in
the current study, we had APOBEC3BmRNA expression data available for 1,132 patients.
Interestingly, although a correlation among APOBEC3B copy number and mRNA expression
was observed, the correlation coefficient was low (spearman’s rho = 0.26, P = 2.210−16). This
suggests that other mechanisms exist that affect APOBEC3BmRNA expression besides APO-
BEC3B copy number.
Discussion
APOBEC3BmRNA expression is upregulated in multiple tumor types and this has been shown
to correlate with an increased mutational load, particularly an increase in C>T transversions
[13,14]. In line with these findings, increased expression of APOBEC3BmRNA was associated
with a poor prognosis in ER-positive breast cancer [15]. At the same time, the 29.5 kb deletion
polymorphism of APOBEC3B was found to be associated with the increased breast cancer risk
in different populations [19–21], although these findings were not confirmed in a Swedish
study [22]. Similar to APOBEC3B overexpression, the APOBEC3B deletion has been shown to
correlate with an increased mutational load [24]. These findings may seem paradoxical, as loss
of APOBEC3B should decrease the mutational load. However, the APOBEC3B deletion poly-
morphism not just deletes APOBEC3B. It also generates a novel fusion transcript (i.e. APO-
BEC3A under the control of the 3’UTR of APOBEC3B) [18]. Consequently, APOBEC3A
mRNA was shown to become more stable, resulting in higher levels of APOBEC3A and, since
APOBEC3A is a more efficient hypermutator than APOBEC3B, more severe DNA damage
[23]. Thus, although the molecular mechanisms behind overexpression of APOBEC3B and the
APOBEC3B deletion polymorphism are very different, they both result in a hypermutator phe-
notype. The hypothesis that the APOBEC3B deletion polymorphism thus may also be associ-
ated with clinical outcome is therefore plausible.
In a study by Gohler et al., the APOBEC3B deletion polymorphism was however, not associ-
ated with breast cancer specific survival in 782 breast cancer cases [22]. Moreover, Cescon et al.
showed that the deletion was not associated with recurrence after treatment for early breast
cancer in METABRIC [16]. Because both studies also included patients that were treated, no
distinction could be made between pure prognosis and therapy response. In the current study,
Table 4. Univariate Cox regression analysis to evaluate the association of calculated APOBEC3B copy number values with the length of PFS.
Study cohort N Patients N Events Univariate analysis
HR (95% CI) P-value
First-line tamoxifen
All patients 329 304 1.00 (0.88–1.14) 0.96
First-line chemotherapy
All patients 226 138 1.06 (0.88–1.29) 0.53
CMF-treated patients 76 52 0.91 (0.65–1.28) 0.58
Anthracyclin-treated patients 150 86 1.19 (0.93–1.52) 0.17
N, number of; HR, hazard ratio; CI, conﬁdence interval; CMF, cyclophosphamide/methotrexate/5-ﬂuorouracil.
Note: The length of PFS was censored at two months after the start of consolidation therapy.
doi:10.1371/journal.pone.0161731.t004
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we examined separately the prognostic and predictive value of APOBEC3B copy number in a
total of 1,756 breast cancer patients. No association between APOBEC3B copy numbers and
the length of MFS was found among 1,076 LNN patients who had not received adjuvant sys-
temic treatment (Fig 2B, Table 2). In addition, an association with the length of MFS was also
not observed among ER-positive or ER-negative breast cancer patients. These results imply
that APOBEC3B copy number is not a prognostic biomarker for breast cancer. The association
between APOBEC3B copy number and the response to treatment in breast cancer patients that
received either first-line tamoxifen or chemotherapy for recurrent disease was also evaluated.
However, we found no association between the type of response for either tamoxifen or chemo-
therapy and APOBEC3B copy number. Thus, besides not having any prognostic value, APO-
BEC3B copy numbers also do not appear to have a predictive value for breast cancer patients.
The copy number analyses in the adjuvant setting, except for the ER-negative LNN analysis,
had sufficient power to conclude that there is no or only a marginal prognostic effect of APO-
BEC3B copy numbers in breast cancer patients (Fig 3). For the copy number analysis in the
advanced setting involving patients treated with first-line tamoxifen, we could draw the same
conclusion (Fig 3). However, for the copy number analysis involving patients treated with first-
line chemotherapy, especially in the subgroup analyses by type of chemotherapy, we cannot
exclude a modest effect of APOBEC3B copy numbers on the length of PFS (Fig 3). Therefore,
replication of the results we observed in the advanced chemotherapy setting in a larger sample
size or population with a higher prevalence of the APOBEC3B deletion polymorphism would
be needed.
Another note is that the assay we used to determine APOBEC3B copy numbers does not dis-
criminate between germline and tumor-specific (i.e. somatic) APOBEC3B deletion. This has no
consequence for the accuracy of the germline copy number determination except for patients
who carry a one-copy deletion and have strong amplification of the remaining APOBEC3B
locus. Patients who do not carry the germline deletion and have either a tumor-specific homo-
zygous deletion or a heterozygous deletion of APOBEC3B in combination with a high tumor
cell percentage may also be misclassified. In this respect, the observed amplification of the
APOBEC3B allele is rather a somatic event than the result of an alteration in the germline. To
date, there has been no report of the APOBEC3B locus being amplified in the germline. Inter-
estingly, in a publically available SNP array data set of 344 breast cancers (accession number
EGAS00001001178 [33]), APOBEC3A copy number status was equal to APOBEC3B copy
number status in all tumors, suggesting that APOBEC3A is always amplified or deleted simulta-
neously with APOBEC3B during breast tumorigenesis.
In our Kaplan-Meier survival analysis we grouped patients with one-copy deletion and two-
copy deletions together to provide a visualization of the estimated survival curves of patients
with a deleted, balanced or amplified APOBEC3B gene. Unfortunately, the population fre-
quency of the 29.5 kb deletion polymorphism of APOBEC3B was too low in this Dutch cohort
to analyze patients who carry a two-copy deletion separately. To illustrate this with a power cal-
culation: we would need a sample size of 4,024 or 11,759 LNN patients to ensure a minimally
detectable hazard ratio of 2 or 1.5, respectively, using a power of 80% and an alpha of 0.05. For
this reason, evaluation of the clinical value of the two-copy deletion should preferably be done
in breast cancer patients from the Asian or American population (i.e. population frequency of
36.9% and 57.7%, respectively)[18].
The observation that the APOBEC3B deletion polymorphism does not seem to have any
impact on the clinical outcome for breast cancer patients, whereas increased expression of
APOBEC3BmRNA does, strengthens the evidence that there are two different molecular
mechanisms in place. Moreover, elevated levels of APOBEC3BmRNA have been shown to
associate with cellular proliferation, whereas the APOBEC3B deletion polymorphism
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associated with activation of immune-related genes [16]. Interestingly, increased lymphocytic
infiltration has been associated with a favorable outcome in some, but not all subtypes of breast
cancer [34,35]. This is in contrast to what has been observed for increased APOBEC3BmRNA
expression, which associated with increased proliferation and poor outcome [15].
Although we observed a correlation between APOBEC3B copy number and mRNA expres-
sion, this correlation was rather weak. As a consequence, the prognostic effect of increased
levels of APOBEC3BmRNA is not necessarily caused by increased APOBEC3B copy numbers.
Other mechanisms thus exist that elevate APOBEC3BmRNA levels. Recently, it was shown
that APOBEC3B interacts with ER to bind to ER binding sites, where it generates C to U tran-
sitions. Furthermore, the presence of APOBEC3B was necessary for histone modification, but
also in order to recruit chromatin remodeling factors to ER binding sites [36]. This may very
well explain why elevated levels of APOBEC3BmRNA are only prognostic in ER-positive
breast cancer patients. Although the APOBEC3B deletion polymorphism does not have any
prognostic or predictive value, it does appear to contribute to breast tumorigenesis by confer-
ring an increased risk to develop breast cancer. However, still little is known regarding the
role of APOBEC3A in breast cancer. Therefore, more studies should be done in order to inves-
tigate the precise effect of the APOBEC3B deletion polymorphism and APOBEC3A-B hybrid
transcript resulting from this deletion. This will provide more insight into APOBEC-mediated
hypermutation.
Supporting Information
S1 Fig. Histogram of the ΔCt values for all 1,756 measured DNA samples and cell line
OCUB-F.
(PDF)
S1 Table. Clinical data of all 1,756 breast cancer patients included in the study.
(XLSX)
Fig 3. Power as a function of the hazard ratio for APOBEC3B copy number in each of the analyzed
subgroups. The dashed horizontal line crosses the curve of each subgroup at the minimal hazard ratio for
which we had 80% power in our APOBEC3B copy number analyses.
doi:10.1371/journal.pone.0161731.g003
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